PDB25 A PATIENT-LEVEL SIMULATION MODEL FOR ECONOMIC EVALUATION OF CINACALCET IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN ITALY  by Eandi, M et al.
A406 Paris Abstracts
from 8.98 o 1.44% to 7.91 o 1.19% , decrease in BMI 0.26 o 1,36 kg/m2 and reduc-
tion in major and minor hypoglycemic events by 97% and 80% respectively. Proba-
bilities of complications, management costs adjustments (including complications) 
were derived from the Czech surveys from 2007. Treatment costs were from June 
2009. Future costs and clinical beneﬁts were discounted at 3.5 % per annum. 
RESULTS: The short-term beneﬁts of switching from BHI 30 to BIAsp 30 are pro-
jected to lead to an increase in discounted quality-adjusted life expectancy of 0.493 
years (4191 o 0.090 versus 3698 o 0.078). Increased total lifetime costs/patient is -
CZK122,594 (534,259 o 1,9925 versus 65,7212 o 21,908) with BIAsp 30. Combining 
costs and clinical outcomes results in an incremental cost-effectiveness per quality-
adjusted life year (QALYs) gained were dominant. CONCLUSIONS: CORE diabetes 
T2 patients sub-cohort simulation in 35 years perspective Czech observational study 
has demonstrated acceptable cost-effectiveness for patients with type 2 diabetes treated 
BIAsp 30. BIAsp 30 treatment was projected to be associated with improvements in 
life expectancy, QALYs and cost saving compared to BHI 30. Sensitivity analyses show 
cost-effectiveness result to be robust.
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OBJECTIVES: Imbalanced levels of parathyroid hormone (PTH), serum calcium (Ca) 
and phosphorus (P) are associated with an increased risk of cardiovascular death and 
fracture. Cinacalcet can regulate these levels in patients with SHPT. Here we describe 
a cost-utility analysis of cinacalcet treatment in SHPT patients in Italy. METHODS: 
We developed a probabilistic patient-level simulation Markov model to simulate the 
effect of cinacalcet on individual Ca, P, and PTH levels (based on data of a European 
multicenter, open-label study); to correlate these levels with mortality and morbidity 
(cardiovascular events, fractures, and parathyroidectomies) recently published in two 
reviews; and to incorporate Italian data for dialysis patients and national cost struc-
ture. Simulation horizon was patient lifetime; simulated treatment alternatives were 
standard treatment (mainly vitamin D sterols and phosphate binders), and cinacalcet 
plus standard treatment. A 3.5% discount rate was applied to life expectancy (LE), 
quality-adjusted life expectancy (QALE), and costs and times in ranges (TiRs) recom-
mended by the KDOQI initiative. Utilities were derived from a prospective cross sec-
tional survey of 180 end-stage renal failure patients with and without co-morbidities. 
Costs were evaluated from the Italian National Healthcare Service perspective. 
RESULTS: Base case results were calculated with 10,000 iterations. Cinacalcet-treated 
patients had a mean (SD) increase in TiR of 5.60 (6.57), 3.45 (6.85), 1.62 (5.64) and 
2.85 (5.60) discounted patient years for PTH, Ca, P, and all parameters, respectively. 
Mean LE extension was 1.16 (3.74) life-years and QALE increase 0.77 (2.63). The 
incremental cost-effectiveness ratio (ICER) calculated considering the TiR varied from 
a5,439 per patient-year in range to a18,748 per patient-year in range (limits for PTH 
and P, respectively). When considering LE, the average ICER results were a26,148/LY 
while when considering QALE, the average ICER was a39,454/quality-adjusted life 
year. CONCLUSIONS: Cinacalcet treatment could be considered cost-effective but 
further investigation is needed.
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OBJECTIVES: To investigate the health economics outcomes of insulin glargine (GLA) 
usage in comparison with insulin NPH (NPH) in diabetes type-2 (DM 2) in real 
practice in the Russian Federation. METHODS: Observational study has been per-
formed in 92 centers in 35 cities of Russia. Two goups of patients (1st- 100 pts received 
GLA o.d, 2d—100 pts—NPH bid) were analized for 6-months period. Group GLA 
had been switched previously from NPH. Efﬁcacy was evaluated according to HbA1ñ 
level as target a7%. The performed CEA analysis included direct costs of medications 
based on average dosages, hospitalizations, days of disability and hypoglycemias. 
RESULTS: The duration of DM 2 was equal in both groups—above 9 years. In 
GLA—87% pts and in 92% NPH pts had high HbA1c at baseline, and 45% and 82% 
(p  0.001) after the end of the study accordingly. Average daily doses of GLA at the 
end of the study were 32.9 UI and for NPH—34,1 UI. Hospitalization rate was higher 
in NPH than in GLA (1,44 vs 0,73 day/patient, p  0.01), disability days (1,37 vs 
0,82 days, p  0.05). The CER was better for GLA vs NPH—a314 RUR and 780 
RUR accordingly. Increase of additional cost was higher for NPH (23.71%) than for 
GLA (7.78%) per patient. CONCLUSIONS: GLA in DM 2 is more cost-effective in 
comparison with NPH due to a better efﬁcacy and safety.
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OBJECTIVES: Type-2 diabetes mellitus (T2DM) is a progressive chronic disease 
placing a huge clinical and ﬁnancial burden on health care services. A recent random-
ized open-label clinical trial (NCT00082381) comparing exenatide with insulin 
glargine provided evidence of the short-term clinical proﬁle of exenatide. The objective 
of this cost-effectiveness analysis was to use these results as the basis for long-term 
projections to estimate the clinical and cost outcomes associated with exenatide treat-
ment versus insulin glargine over a 15-year time horizon in a Turkish setting. 
METHODS: The analysis used the previously published and validated IMS Core 
Diabetes Model, comprised of a series of Markov-based submodels simulating the 
major complications of diabetes (cardiovascular, renal, eye and neurological disease). 
Using baseline characteristics (mean age 58.9 years; 55.7% male; mean HbA1c 8.21%; 
mean duration of diabetes 9.56 years), complications and concomitant medications 
from study NCT00082381, analysis was performed using a non-parametric bootstrap-      
ping approach where disease progression was simulated to estimate costs, life expect-
ancy and quality-adjusted life expectancy (QALE). RESULTS: Exenatide treatment 
was projected to improve life expectancy (mean[SD] years: 8.41[0.09]) and QALE 
(mean[SD] quality-adjusted life years [QALY]: 6.00[0.07]) compared with insulin 
glargine (mean[SD] years: 8.38[0.08]; mean[SD] QALY: 5.62[0.06]), while also delay-
ing the onset of diabetes-related complications (years to onset: exenatide: 4.04; insulin 
glargine: 4.00). Lifetime direct medical costs were higher for exenatide with a 
mean(SD) of 53,573(819) New Turkish Lira (YTL) compared with insulin glargine 
YTL 42,361(770). The incremental cost-effectiveness ratio (ICER) based on QALE 
for exenatide was YTL 30,018 per QALY gained versus insulin glargine. CONCLU-
SIONS: The outcome of this analysis was that exenatide treatment was projected to 
improve life expectancy and QALE and reduce cumulative incidence of most diabetes-
related complications including cardiovascular disease, compared with insulin glargine. 
By current Turkish standards, the ICER for exenatide would be considered to repre-
sent good value for money.
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OBJECTIVES: To estimate the cost-utility of vildagliptin in the treatment of diabetes 
mellitus type 2, in combination with metformin, compared to the standard strategy        
of treatment in Poland: combination of metformin and sulphonylure.       METHODS: 
The cost-utility analysis is based on Markov decision model (package Tree Age Pro        
2008). The following strategies of treatment were compared: vildagliptin (50 mg twice     
daily) versus glimepiride (mean dose 4,5 mg/day) both added to metformin (mean dose            
1892 mg/day). Direct medical costs were considered: cost of oral antidiabetic drugs          
(OAD), cost of insulin, additional costs of treatment of type 2 diabetes (e.g. test strips, 
lancets), cost of general practitioner, cost of specialist visits, cost of complications of         
type 2 diabetes mellitus treatment. Polish cost data was used. The units of effectiveness    
in the analysis were quality adjusted life years (QALY) and life years gained (LYG). 
The outcome of the analysis was incremental cost-effectiveness ratio (ICER), which 
presents the cost of gaining one additional unit of QALY or LYG in the case of using 
therapy with vildagliptin instead of the comparator. Data concerning clinical effective-
ness of compared interventions and also of other strategies of treatment (used after 
OAD treatment) were taken from RCT studies, long term studies and systematic 
reviews. The target population consisted of adult patients with diagnosed diabetes 
mellitus type 2, inadequately controlled with metformin in monotherapy. Both payer’s  
perspective (National Health Fund and patient) and a lifelong time horizon were 
assumed in the analysis. RESULTS: Cost of gaining one additional unit of QALY 
and one additional unit of LYG in the case of using combination therapy 
vildagliptinmetformin instead of therapy glimepiridemetformin is 58,483 PLN and 
589,575 PLN, respectively. CONCLUSIONS: Assuming the Polish acceptable thresh- 
old which is 91,914 PLN, treatment with combination of vildagliptin and metformin           
is cost-effective.
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OBJECTIVES: Diabetic nephropathy is a frequent and serious complication in patients 
with type-2 diabetes mellitus (DM), and it is the most frequent cause of End Stage 
Renal Disease (ESRD) in industrialized countries. The global incidence of ESRD con-
tinues to rise, and ESRD patients requires intensive and costly treatments such as 
dialysis or transplantation; thus, the burden of illness is growing and the resources 
allocated to treatment are increasing. The objective of our study was to evaluate the 
economic impact of losartan added to the standard care administered to diabetic 
subjects with End-Stage Renal Disease in Italy. METHODS: We conducted a cost-
effectiveness analysis comparing the economic and clinical outcomes deriving from the 
administration of additional losartan to standard care versus standard care alone in 
